Iovance Biotherapeutics (LTS:0JDK) Change In Payables And Accrued Expense : $33.9 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Iovance Biotherapeutics Change In Payables And Accrued Expense?

Iovance Biotherapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $4.3 Mil. It means Iovance Biotherapeutics's Accounts Payable & Accrued Expense increased by $4.3 Mil from Dec. 2024 to Mar. 2025 .

Iovance Biotherapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $0.7 Mil. It means Iovance Biotherapeutics's Accounts Payable & Accrued Expense increased by $0.7 Mil from Dec. 2023 to Dec. 2024 .

Iovance Biotherapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Iovance Biotherapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Change In Payables And Accrued Expense Chart

Iovance Biotherapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

21.15

27.66

1.18

24.60

0.74

Iovance Biotherapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-28.83	4.42	27.14	-1.99	4.30

Iovance Biotherapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.9 Mil.

Iovance Biotherapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (LTS:0JDK) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

IOVA:USA 2LB:Germany

Address

825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics Headlines

No Headlines